Cloudbreak Pharma Inc. (HKEX: 2592), a clinical-stage ophthalmic biopharmaceutical company specializing in proprietary Multi Kinase Inhibitor (MKI) discovery platforms, has released encouraging top-line results from its Phase 3 clinical trial evaluating CBT-001 as a potential breakthrough treatment for pterygium.
These findings represent a significant milestone in ophthalmology, marking the first time an investigational drug has demonstrated true disease-modifying activity in pterygium through statistically significant improvements in both vascular redness and lesion size.
Key Efficacy Highlights
The multi-regional, double-masked, randomized, vehicle-controlled Phase 3 study (Trial CS-301, NCT05456425) evaluated two distinct doses of CBT-001 ophthalmic emulsion (0.1% and 0.2%) administered twice daily over 24 months compared to a vehicle control.
Reduction in Conjunctival Hyperemia: Both the 0.1% and 0.2% doses of CBT-001 achieved statistically significant improvements in conjunctival hyperemia (redness associated with the vascularized lesion) at Month 3 compared to the vehicle group (). Clinical benefits were observed as early as Week 2 and were consistently maintained through every follow-up visit up to Month 12.
Prevention of Lesion Progression: Both doses demonstrated statistically significant efficacy in preventing the progression of pterygium lesion length at Month 12 compared to vehicle (). The treatment-versus-vehicle benefit reached approximately 10% of baseline measurements, with the observed therapeutic effect continuing to climb without reaching a plateau by Month 12.
Safety and Tolerability Profile
CBT-001 demonstrated a favorable and manageable safety profile across the study population:
Most Common Adverse Event: Superficial punctate keratitis was reported in 20% of patients in the CBT-001 0.1% cohort, compared to 8% in the vehicle group. The vast majority of these cases successfully resolved with standard artificial tears.
Dose-Dependent Incidence: A comparable safety profile was observed in the higher 0.2% dose group, though individual adverse events occurred at a higher incidence rate. All other individual adverse events were reported in 2% or fewer patients within the 0.1% group.
Trial Demographics and Study Design
The robust dataset encompasses 659 patients globally, randomized across three arms:
CBT-001 0.1%: 164 patients
CBT-001 0.2%: 329 patients
Vehicle Control: 166 patients
The study cohort comprised 58% male and 42% female participants. Enrollment commenced in the United States in June 2022 and subsequently expanded to clinical sites across China, New Zealand, Australia, and India. The study protocol incorporates a 12-month double-masked extension to gather up to 24 months of comprehensive safety data.
Clinical Significance and Market Context
Pterygium—frequently referred to as "surfer's eye"—is a triangular fibrovascular growth of the conjunctiva onto the cornea, largely driven by chronic ultraviolet (UV) exposure. It causes chronic irritation, foreign body sensation, dryness, cosmetic concerns, and potentially severe visual impairment.
High Unmet Medical Need: Pterygium affects an estimated 1 billion people globally, including 13 million individuals in the United States. Among US patients, roughly 6.5 million seek professional eye care annually, and 2.5 million are formally diagnosed each year.
Absence of Approved Therapeutics: Currently, there are no FDA-approved disease-modifying drug therapies for pterygium. Patients rely primarily on palliative care, such as artificial tears, dry-eye medications, or off-label use of NSAIDs and corticosteroids, which carry significant long-term limitations.
Dr. Abu Abraham, Chief Medical Officer at Cloudbreak Pharma, emphasized the potential paradigm shift:
"CBT-001 has the potential to become the first disease-modifying therapy in pterygium, and we look forward to engaging with the FDA as soon as practical to determine next steps for this potential first-in-class therapy."
Future Outlook and Corporate Pipeline
Cloudbreak Pharma is currently finalizing comprehensive secondary analyses of the Phase 3 data. The company plans to request a meeting with the U.S. Food and Drug Administration (FDA) at the earliest opportunity to review findings and map out regulatory pathways for the CBT-001 New Drug Application (NDA) submission.
Beyond CBT-001, Cloudbreak is advancing its broader ophthalmic pipeline:
CBT-004: A secondary MKI candidate targeting pinguecula (affecting roughly half of individuals over age 70), which recently completed a successful End-of-Phase 2 meeting with the FDA and is advancing toward Phase 3 trials.
SFA+ Platform: Early-to-late-stage proprietary semi-fluorinated alkane assets targeting front- and back-of-eye diseases.
For further corporate updates and investor information, visit the official Cloudbreak Pharma Website.
